Youth in transition: Study protocol of a prospective cohort study into the long-term course of addiction, mental health problems and social functioning in youth entering addiction treatment.
Adolescents
Long-term course of SUD
Prospective cohort study
Substance use disorder
Youth addiction treatment
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
04 12 2021
04 12 2021
Historique:
received:
06
07
2021
accepted:
04
10
2021
entrez:
5
12
2021
pubmed:
6
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Substance use disorders (SUDs) are prevalent in the general population, tend to follow a chronic course, are associated with many individual and social problems, and often have their onset in adolescence. However, the knowledge base from prospective population surveys and treatment-outcome studies on the course of SUD in adolescents is limited at best. The present study aims to fill this gap and focuses on a subgroup that is particularly at risk for chronicity: adolescents in addiction treatment. We will investigate the rate of persistent SUD and its predictors longitudinally from adolescence to young adulthood among youth with DSM-5 SUD from the start of their addiction treatment to 2 and 4 years following treatment-entry. In addition to SUD, we will investigate the course of comorbid mental disorders, social functioning, and quality of life and their association with SUD over time. In a naturalistic, multi-center prospective cohort design, we will include youths (n = 420), who consecutively enter addiction treatment at ten participating organizations in the Netherlands. Inclusion is prestratified by treatment organization, to ensure a nationally representative sample. Eligible youths are 16 to 22 years old and seek help for a primary DSM-5 cannabis, alcohol, cocaine or amphetamine use disorder. Assessments focus on lifetime and current substance use and SUD, non-SUD mental disorders, family history, life events, social functioning, treatment history, quality of life, chronic stress indicators (hair cortisol) and neuropsychological tests (computerized executive function tasks) and are conducted at baseline, end of treatment, and 2 and 4 years post-baseline. Baseline data and treatment data (type, intensity, duration) will be used to predict outcome - persistence of or desistance from SUD. There are remarkably few prospective studies worldwide that investigated the course of SUD in adolescents in addiction treatment for longer than 1 year. We are confident that the Youth in Transition study will further our understanding of determinants and consequences of persistent SUD among high-risk adolescents during the critical transition from adolescence to young adulthood. The Netherlands National Trial Register Trial NL7928 . Date of registration January 17, 2019.
Sections du résumé
BACKGROUND
Substance use disorders (SUDs) are prevalent in the general population, tend to follow a chronic course, are associated with many individual and social problems, and often have their onset in adolescence. However, the knowledge base from prospective population surveys and treatment-outcome studies on the course of SUD in adolescents is limited at best. The present study aims to fill this gap and focuses on a subgroup that is particularly at risk for chronicity: adolescents in addiction treatment. We will investigate the rate of persistent SUD and its predictors longitudinally from adolescence to young adulthood among youth with DSM-5 SUD from the start of their addiction treatment to 2 and 4 years following treatment-entry. In addition to SUD, we will investigate the course of comorbid mental disorders, social functioning, and quality of life and their association with SUD over time.
METHODS/DESIGN
In a naturalistic, multi-center prospective cohort design, we will include youths (n = 420), who consecutively enter addiction treatment at ten participating organizations in the Netherlands. Inclusion is prestratified by treatment organization, to ensure a nationally representative sample. Eligible youths are 16 to 22 years old and seek help for a primary DSM-5 cannabis, alcohol, cocaine or amphetamine use disorder. Assessments focus on lifetime and current substance use and SUD, non-SUD mental disorders, family history, life events, social functioning, treatment history, quality of life, chronic stress indicators (hair cortisol) and neuropsychological tests (computerized executive function tasks) and are conducted at baseline, end of treatment, and 2 and 4 years post-baseline. Baseline data and treatment data (type, intensity, duration) will be used to predict outcome - persistence of or desistance from SUD.
DISCUSSION
There are remarkably few prospective studies worldwide that investigated the course of SUD in adolescents in addiction treatment for longer than 1 year. We are confident that the Youth in Transition study will further our understanding of determinants and consequences of persistent SUD among high-risk adolescents during the critical transition from adolescence to young adulthood.
TRIAL REGISTRATION
The Netherlands National Trial Register Trial NL7928 . Date of registration January 17, 2019.
Identifiants
pubmed: 34863131
doi: 10.1186/s12888-021-03520-8
pii: 10.1186/s12888-021-03520-8
pmc: PMC8642918
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605Informations de copyright
© 2021. The Author(s).
Références
Borderline Personal Disord Emot Dysregul. 2021 Feb 1;8(1):3
pubmed: 33517905
Psychol Rev. 1993 Oct;100(4):674-701
pubmed: 8255953
Subst Abus. 2013;34(1):33-42
pubmed: 23327502
Addiction. 2014 Feb;109(2):303-11
pubmed: 24033662
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
J Stud Alcohol Drugs. 2008 May;69(3):420-9
pubmed: 18432385
J Subst Abuse Treat. 2014 Jul;47(1):58-72
pubmed: 24629886
J Abnorm Psychol. 2004 Nov;113(4):483-98
pubmed: 15535782
Dev Psychopathol. 2015 Feb;27(1):253-77
pubmed: 25017089
Drug Alcohol Depend. 2016 Aug 01;165:159-67
pubmed: 27344196
Drug Alcohol Depend. 2007 Apr;88 Suppl 1:S60-70
pubmed: 17257779
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Psychol Med. 2016 Mar;46(4):877-89
pubmed: 26620720
J Subst Abuse Treat. 2013 Feb;44(2):145-58
pubmed: 22763198
Addiction. 2008 Aug;103(8):1361-70
pubmed: 18855826
Drug Alcohol Depend. 2005 Jul;79(1):11-22
pubmed: 15943940
J Psychiatr Res. 2015 Nov;70:38-49
pubmed: 26424422
J Consult Clin Psychol. 2011 Jun;79(3):296-306
pubmed: 21500886
Behav Processes. 2015 Feb;111:55-9
pubmed: 25447508
Br J Psychiatry. 2003 Apr;182:330-6
pubmed: 12668409
Child Abuse Negl. 2009 Nov;33(11):815-25
pubmed: 19853301
Drug Alcohol Depend. 2010 Mar 1;107(2-3):171-81
pubmed: 19926231
Addict Behav. 2009 Dec;34(12):1042-55
pubmed: 19683400
Dev Cogn Neurosci. 2018 Aug;32:80-96
pubmed: 29559216
Dev Psychopathol. 2004 Fall;16(4):1029-46
pubmed: 15704826
Addiction. 2004 Nov;99 Suppl 2:129-39
pubmed: 15488111
Addiction. 2010 May;105(5):862-71
pubmed: 20331557
Schizophr Bull. 2012 Nov;38(6):1288-96
pubmed: 22516147
Arch Gen Psychiatry. 2009 Jul;66(7):764-72
pubmed: 19581568
Addiction. 2008 Mar;103(3):439-49; discussion 450-1
pubmed: 18269364
Behav Res Methods. 2018 Feb;50(1):236-249
pubmed: 28289888
J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):1020-36
pubmed: 23021478
Psychoneuroendocrinology. 2013 Aug;38(8):1220-35
pubmed: 23253896
Stat Med. 2000 Apr 30;19(8):1059-79
pubmed: 10790680
Alcohol Clin Exp Res. 2000 Jun;24(6):882-91
pubmed: 10888079
Curr Drug Abuse Rev. 2010 Sep;3(3):189-95
pubmed: 20298174
Addiction. 2008 Sep;103(9):1450-60
pubmed: 18783500
Early Interv Psychiatry. 2018 Feb;12(1):3-14
pubmed: 28782283
Addict Behav. 2003 Aug;28(6):1175-82
pubmed: 12834660
Neuropsychologia. 1982;20(3):249-62
pubmed: 7121793
Dev Psychopathol. 2004 Winter;16(1):193-213
pubmed: 15115071
Prev Med. 2021 Jul;148:106545
pubmed: 33812854
J Consult Clin Psychol. 2005 Dec;73(6):1005-14
pubmed: 16392974
J Appl Res Intellect Disabil. 2018 Jan;31(1):e59-e67
pubmed: 27925356
Int Rev Psychiatry. 2009 Apr;21(2):96-103
pubmed: 19367503
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Alcohol Clin Exp Res. 2020 Aug;44(8):1551-1560
pubmed: 32583872
Neuroimage. 2003 Aug;19(4):1439-48
pubmed: 12948701